Table 1.
Characteristics of the study cohort
| No HCT | Allogeneic-HCT | Autologous HCT | Total | p-value | |
|---|---|---|---|---|---|
| Number | 69 | 57 | 28 | 154 | |
| Median age (range) | 60 (18–79) | 51 (23–70) | 60 (22–77) | 54 (18–79) | 0.03 |
| Sex, n (%) Female Male |
28 (41) 41 (59) |
22 (39) 35 (61) |
15 (54) 13 (46) |
65 (42) 89 (58) |
0.39 |
| Malignancy, n (%) Leukemia Lymphoma Myeloma |
43 62) 13 (19) 13 (19) |
34 (60) 20 (35) 3 (5) |
2 (7) 12 (43) 14 (50) |
79 (51) 45 (29) 30 (20) |
< 0.001* |
| Recent chemotherapy (within 1 month prior to RSV), n (%) | 52 (75) | 17 (30) | 13 (46) | 82 (53) | < 0.001* |
| Corticosteroid (within 1 month prior to RSV diagnosis), n (%) | 43 (62) | 29 (51) | 22 (79) | 94 (61) | 0.046 |
| Neutropenia at RSV diagnosis (ANC <500 cells/mm3) n (%) | 35 (51) | 6 (11) | 6 (21) | 47 (31) | < 0.001 |
| Lymphocytopenia at RSV diagnosis (ALC <200 cells/mm3), n (%) | 33 (48) | 15 (26) | 6 (21) | 54 (35) | 0.01 |
| Ribavirin therapy, n (%) None URTI stage LRTI stage |
19 (28) 3 (4) 47 (68) |
3 (5) 6 (11) 48 (84) |
1 (4) 5 (18) 22 (78) |
23 (15) 14 (9) 117 (76) |
< 0.001 |
| RSV LRTI Possible Proven |
60 (87) 9 (13) |
48 (84) 9 (16) |
23 (82) 5 (18) |
131 (85) 23 (15) |
0.84 |
| Organisms detected in BAL None RSV RSV + co-pathogens Co-pathogens |
12 6 3 2 |
8 7 2 6 |
6 5 0 4 |
26 18 5 12 |
0.540 |
Abbreviation. HM: hematologic malignancy; HCT: hematopoietic cell transplant; RSV: respiratory syncytial virus; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; URTI: upper respiratory tract infection; LRTI: lower respiratory tract infection; BAL: bronchoalveolar lavage